Impax Laboratories Inc. said a treatment for Parkinson’s Disease that it is testing with GlaxoSmithKline did well in a Phase III clinical trial.
Hayward-based Impax (NASDAQ: IPXL) has been working since December with GlaxoSmithKline (NYSE: GSK) on the drug, IPX-066.
Impax, which typically focuses on generic drugs, is developing IPX-066 through its “branded products unit,” Impax Pharmaceuticals.
No comments:
Post a Comment